Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00222235
Status:
COMPLETED
Last Update Posted:
2019-08-20
First Post:
2005-09-13
Brief Title:
Adjunctive Treatment for Decreasing Symptoms of Schizophrenia
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Cognitive and Negative Symptoms in Schizophrenia Trial CONSIST
Status:
COMPLETED
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will determine the effectiveness of treatment with glycine or d-cycloserine in addition to a normal antipsychotic regimen in improving negative symptoms and cognitive impairments in patients with schizophrenia
Detailed Description:
A double-blind placebo controlled clinical trial to examine whether adjunctive treatment with glycine or d-cycloserine compared to placebo will improve negative symptoms and cognitive impairments in patients with schizophrenia who remain on their normal antipsychotic regimen
Multicenter randomized double-blinded placebo controlled parallel-groups clinical trial designed to test the hypothesis that interventions glycine or d-cycloserine intended to increase glutamatergic activity by action at the NMDA receptor will reduce persistant negative symptoms and cognitive impairments of patients with schizophrenia or schizoaffective disorder After an initial screening phase to establish clinical stability and eligibility patients were assigned to one of three adjunctive treatments placebo d-cycloserine or glycinefor 16 weeks of double-blind treatment Patients remained on a stable dose of antipsychotic therapy other than clozapine throughout the study
Multicenter randomized double-blinded placebo controlled parallel-groups clinical trial designed to test the hypothesis that interventions glycine or d-cycloserine intended to increase glutamatergic activity by action at the NMDA receptor will reduce persistant negative symptoms and cognitive impairments of patients with schizophrenia or schizoaffective disorder After an initial screening phase to establish clinical stability and eligibility patients were assigned to one of three adjunctive treatments placebo d-cycloserine or glycinefor 16 weeks of double-blind treatment Patients remained on a stable dose of antipsychotic therapy other than clozapine throughout the study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01MH059807 | NIH | None | httpsreporternihgovquickSearchR01MH059807 |